The therapeutic potential of NUDT-selective inhibitors has already been shown—NUDT1-selective inhibitors have shown efficacy in multiple studies in vitro and in vivo [67,68,69,70], and the NUDT5-selective inhibitor TH1457 blocks cell proliferation in breast cancer cells [71]. Here, NUDT5 is linked to breast carcinoma.